Sex disparities in cancer mortality and survival
- PMID: 21750167
- PMCID: PMC3153584
- DOI: 10.1158/1055-9965.EPI-11-0246
Sex disparities in cancer mortality and survival
Abstract
Background: Previous research has noted higher cancer mortality rates and lower survival among males than females. However, systematic comparisons of these two metrics by sex have been limited.
Methods: We extracted U.S. vital rates and survival data from the Surveillance, Epidemiology and End Results Database for 36 cancers by sex and age for the period 1977 to 2006. We compared sex-specific mortality rates and examined male-to-female mortality rate ratios (MRR). We also extracted case data which included age and date of diagnosis, sex, primary cancer site, tumor stage and grade, survival time, vital status, and cause of death. Relative cancer-specific HRs for death in the 5-year period following diagnosis were estimated with Cox proportional hazards models, adjusted for covariates.
Results: For the vast majority of cancers, age-adjusted mortality rates were higher among males than females with the highest male-to-female MRR for lip (5.51), larynx (5.37), hypopharynx (4.47), esophagus (4.08), and urinary bladder (3.36). Cancer-specific survival was, for most cancers, worse for males than females, but such disparities were drastically less than corresponding MRRs [e.g., lip (HR = 0.93), larynx (HR = 1.09), hypopharynx (HR = 0.98), esophagus (HR = 1.05), and urinary bladder (HR = 0.83)].
Conclusions: Male-to-female MRRs differed markedly while cancer survival disparities were much less pronounced. This suggests that sex-related cancer disparities are more strongly related to etiology than prognosis.
Impact: Future analytic studies should attempt to understand causes of observed sex disparities in cancer.
©2011 AACR.
Figures
Similar articles
-
Cancer of the Larynx-20-Year Comparative Survival and Mortality Analysis by Age, Sex, Race, Stage, Grade, Cohort Entry Time-Period, Disease Duration and ICD-O-3 Topographic Primary Sites-Codes C32.0-9: A Systematic Review of 43,103 Cases for Diagnosis Years 1975-2017: (NCI SEER*Stat 8.3.9).J Insur Med. 2024 Jul 1;51(2):92-110. doi: 10.17849/insm-51-2-92-110.1. J Insur Med. 2024. PMID: 39266004
-
Disparities by Race, Age, and Sex in the Improvement of Survival for Major Cancers: Results From the National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) Program in the United States, 1990 to 2010.JAMA Oncol. 2015 Apr;1(1):88-96. doi: 10.1001/jamaoncol.2014.161. JAMA Oncol. 2015. PMID: 26182310 Free PMC article.
-
Cancer of the Nasal Cavity, Middle Ear and Accessory Sinuses - 15 Year Comparative Survival and Mortality Analysis by Age, Sex, Race, Stage, Grade, Cohort Entry Time-Period, Disease Duration and Topographic Primary Sites: A Systematic Review of 13,404 Cases for Diagnosis Years 2000-2017: (NCI SEER*Stat 8.3.8).J Insur Med. 2024 Jul 1;51(2):77-91. doi: 10.17849/insm-51-2-77-91.1. J Insur Med. 2024. PMID: 39266003
-
20-Year Comparative Survival and Mortality of Cancer of the Stomach by Age, Sex, Race, Stage, Grade, Cohort Entry Time-Period, Disease Duration & Selected ICD-O-3 Oncologic Phenotypes: A Systematic Review of 157,258 Cases for Diagnosis Years 1973-2014: (SEER*Stat 8.3.4).J Insur Med. 2019;48(1):5-23. doi: 10.17849/insm-48-1-1-19.1. Epub 2019 Oct 14. J Insur Med. 2019. PMID: 31609640
-
Plasma Cell Myeloma - 20-Year Comparative Survival and Mortality of Three Plasma Cell Myeloma ICD-O-3 Oncologic Phenotypes by Age, Sex, Race, Stage, Cohort Entry Time-Period and Disease Duration: A Systematic Review of 111,041 Cases for Diagnosis Years 1973-2014: (SEER*Stat 8.3.4).J Insur Med. 2018;47(4):203-211. doi: 10.17849/insm-47-04-1-9.1. Epub 2019 Jan 22. J Insur Med. 2018. PMID: 30668210
Cited by
-
Estimating Health Expectancy in Japanese Communities Using Mortality Rate and Disability Prevalence.JMA J. 2024 Jan 15;7(1):21-29. doi: 10.31662/jmaj.2023-0058. Epub 2023 Dec 27. JMA J. 2024. PMID: 38314416 Free PMC article.
-
G Protein-Coupled Estrogen Receptor in Cancer and Stromal Cells: Functions and Novel Therapeutic Perspectives.Cells. 2021 Mar 17;10(3):672. doi: 10.3390/cells10030672. Cells. 2021. PMID: 33802978 Free PMC article. Review.
-
Comparison of in-patient costs for children treated on the AAML0531 clinical trial: A report from the Children's Oncology Group.Pediatr Blood Cancer. 2015 Oct;62(10):1775-81. doi: 10.1002/pbc.25569. Epub 2015 May 6. Pediatr Blood Cancer. 2015. PMID: 25946708 Free PMC article. Clinical Trial.
-
Y genetic variation and phenotypic diversity in health and disease.Biol Sex Differ. 2015 Mar 13;6:6. doi: 10.1186/s13293-015-0024-z. eCollection 2015. Biol Sex Differ. 2015. PMID: 25866616 Free PMC article.
-
Sex-, feeding-, and circadian time-dependency of P-glycoprotein expression and activity - implications for mechanistic pharmacokinetics modeling.Sci Rep. 2019 Jul 19;9(1):10505. doi: 10.1038/s41598-019-46977-0. Sci Rep. 2019. PMID: 31324853 Free PMC article.
References
-
- US Institute of Medicine. Exploring the biological contributions to human health: does sex matter? J Womens Health Gend Based Med. 2001;10:433–9. - PubMed
-
- Shang Y. Hormones and cancer. Cell Res. 2007;17:277–9. - PubMed
-
- Whiteman DC, Sadeghi S, Pandeya N, Smithers BM, Gotley DC, Bain CJ, et al. Combined effects of obesity, acid reflux and smoking on the risk of adenocarcinomas of the oesophagus. Gut. 2008;57:173–80. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources